Uveitis represents a wide spectrum of intraocular inflammatory conditions and includes various autoimmune and infectious etiologies. The relevance of animal models of uveitis to human diseases remains a key issue with major implications for the translational research and development of therapeutic strategies. Histopathological findings in patients with Vogt-Koyanagi-Harada disease, birdshot retinochoroidopathy and anterior uveitis are correlated to those observed in different animal models. Even though evidence based on histopathology is usually irrefutable, similar features may be due to different disease mechanisms. Analysis of triggering factors, determination of cellular populations and immune microenvironment should prevail over clinical phenotype evaluation. There is a controversy in correlating the clinical finding of nummular chorioretinal scars, commonly referred to as Dalen-Fuchs nodules, seen in the periphery of fundus in patients with chronic Vogt-Koyanagi-Harada disease with histologic observations made on such enucleated eyes. Although histopathology of the lesions consisted of focal chorioretinal scars with loss of RPE, there was no consensus about the histologic nature of the nummular chorioretinal scars, particularly whether they represent Dalen-Fuchs nodules. Based on the immunogenetic background, there may be different forms of one specific disease with variable phenotypic expression. This review discusses the importance of experimental models in the light of immunologic alterations and histopathological features in human uveitic entities.
Bahram Bodaghi, MD, PhD
Department of Ophthalmology
Pitié-Salpêtrière Hospital, 47–83 bd de l’Hôpital
FR–75013 Paris (France)
Published online: April 18, 2008
Number of Print Pages : 3
Number of Figures : 0, Number of Tables : 0, Number of References : 0
Ophthalmic Research (Journal for Research in Experimental and Clinical Ophthalmology)
Vol. 40, No. 3-4, Year 2008 (Cover Date: April 2008)
Journal Editor: Pleyer U. (Berlin)
ISSN: 0030–3747 (Print), eISSN: 1423–0259 (Online)
For additional information: http://www.karger.com/ORE
Copyright / Drug Dosage
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.